Skip to content
Menu

Cantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $170

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $125 to $170.

Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $125 to $170.

Read at benzinga.com